682.1K XNAS Volume
XNAS 19 Mar, 2025 5:30 PM (EDT)
Xencor Inc Key Metrics
Select
All financials are in USD Million and price data in USD
VIEW MORE
Low Financial Strength
Expensive Valuation
Technically Neutral
Momentum Trap
These stocks are the ones with poor quality and also financials and technical ranging from bad to medium score. This indicates that investors should be highly watchful with these stocks.
View Similar
Embed DVM
Check Before You Buy
VIEW FULL CHECKLISTLow rank
6Positive15Negative
28.6% Pass in checklist
Check P/E Buy Sell Zone
This stock has negative PE
Xencor Inc Stock Price Analysis
Day Price Range | 13.1 (LTP) 12.613.2 LowHigh |
Week Price Range | 13.1 (LTP) 12.513.5 LowHigh |
Month Price Range | 13.1 (LTP) 12.516.3 LowHigh |
52 Week Price Range | 13.1 (LTP) 12.527.2 LowHigh |
Xencor Inc Live Price Chart
Switch to TradingView
Fetching data ...
Revenue forecast
Hit
Xencor Inc's Revenue was higher than average estimate 2 times in past 3 years
EPS forecast
Current EPS
Avg. Estimate
Hit
EPS is expected to grow by 27.1% in FY25
Consensus Recommendation
11 ANALYST Recommendations
BUY
The consensus recommendation from 11 analysts for Xencor Inc is BUY
Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get Xencor Inc Stock Analysis
Xencor Inc stock analysis with key metrics, changes, and trends.
Xencor Inc Metric | VALUE | CHANGE % | TREND | ANALYSIS | |
---|---|---|---|---|---|
Annual Revenue | $110.49 M | 36.72% | negative |
| |
Annual Net Profit | $232.62 M | 74.73% | negative |
| |
Price to Earning Ratio | -3.98 | - | negative |
| |
Stock Price | $13.14 | -42.27% | negative |
| |
Quarterly Revenue | $52.79 M | 3.58% | positive |
| |
Quarterly Net profit | $45.55 M | 74.22% | negative |
| |
Debt to Equity Ratio | 0.34 | - | positive |
| |
Return on Equity(ROE) | -34.74 % | -34.74% | negative |
| |
Mutual Fund Holding | 72.82 % | -1.19% | negative |
| |
Promoter Share Holding | 1.66 % | 0.29% | positive |
| |
Interest Coverage Ratio | -5.41 | - | negative |
| |
Institutional Holding | 106.77 % | 0% | neutral |
|
Loading data..
Xencor Inc - Company Profile
What does Xencor Inc do?

Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.
Xencor Inc Management structure
All Gross Remunerations are in USD